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Background: Peripheral artery disease (PAD) is not only a serious complication but also a risk factor to predict
prognosis in the patients with hemodialysis (HD). Ankle-brachial blood pressure index (ABI) has been widely
used for detection of PAD. Skin perfusion pressure (SPP) was used for early detection of PAD by measurement
of microcirculation of subcutaneous tissue. We studied the effectiveness of ABI and SPP to predict prognosis of
HD patients.
Methods: Both SPP and ABI were measured in 45 HD outpatients in Nagahara Hospital. The patients were
followed with a mean observational period of 44.4 months to evaluate the association of ABI or SPP value
with any-cause mortality.
Results: The median ABI and SPP values in all patients were 1.15 and 70.0 mmHg, respectively, and the
patients were classified into two groups with the median value used as the cutoff points. In Kaplan-Meier
analysis, the lower SPP group showed significantly worse survival curve than the higher SPP group while
there were no differences between ABI groups. Cox proportional hazards model demonstrated SPP values
are independent and significant risk factors for mortality.
Conclusions: These results suggest evaluation of PAD by SPP measurement is useful to predict prognosis
of HD patients.Background
The annual mortality in chronic dialysis patients in
Japan is less than 10% although the age of the patients
has become higher and the proportion of the patients
with long-term dialysis has increased [1]. The frequent
causes of death in the hemodialysis patients are heart
failure and cardiovascular diseases [2]. The prevalence of
heart disease and vascular disease is expected to rise
with increased elderly patients, increased patients with
diabetes mellitus, and increased long HD patients [3, 4].
Thus, indicators should be required to predict heart fail-
ure and cardiovascular diseases in HD patients.
Peripheral artery disease (PAD) is a common compli-
cation in the hemodialysis patients [5, 6]. The patients* Correspondence: nanami@cam.hi-ho.ne.jp
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ary heart disease and congestive heart failure as well as
foot lesion in many cohort studies [7]. High prevalence
of PAD is associated with a number of factors including
increasing number of HD patients from diabetes, HD in-
duction at older age, and complication of atherosclerosis
due to abnormal calcium metabolism at the preserved
stage of renal failure [8]. Some reports suggest renal
insufficiency itself is an independent risk factor of PAD
in the HD patients with or without diabetes [9].
Therefore, PAD is not only a serious complication of
HD but also a risk factor to predict cardiovascular dis-
ease. Thus, early diagnosis of PAD is an important issue
for the hemodialysis patients. Most HD patients usually
do not have any symptoms at the initial stage of PAD,
and early detection for PAD is pretty difficult [10]. Some
patients undergo amputation of the lower extremities as
the diagnosis of PAD is delayed. Amputation does notle is distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
ive appropriate credit to the original author(s) and the source, provide a link to
changes were made. The Creative Commons Public Domain Dedication waiver
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Table 1 Characteristics of the study participants
All patients (n = 45)
Age (years) 62.7 ± 12.4
Gender (m/f) 31:14
Duration of hemodialysis (years) 7.3 ± 5.1
Quantity of blood flow (ml/min) 202.7 ± 24.4
Dialysis time (h) 4.0 ± 0.4
Primary cause of ESKD, n (%)
Diabetic nephropathy 17 (38.0)
Chronic glomerulonephritis 17 (38.0)
Nephrosclerosis 2 (4.4)
Polycystic kidney disease 2 (4.4)
Unknown and others 7 (15.6)




Hemoglobin (g/dI) 10.1 ± 1.0
Albumin (f/dI) 4.1 ± 0.4
Ca (mg/dI) 9.4 ± 0.7
P (mg/dI) 5.1 ± 1.2
BUN (mg/dI) 69.3 ± 12.4
Cre (mg/dI) 10.9 ± 2.0
i-PTH (pg/dI) 176.9 ± 112.0
LVD (mm) 51.1 ± 5.1
LVEF (%) 66.6 ± 9.0
LVD left ventricular end-diastolic diameter, LVEF left ventricular ejection
fraction, i-PTH intact PTH
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but also influence prognosis since it frequently causes
critical infectious disease leading to death [11, 12]. The
patients with PAD have been reported to have poor
prognosis due to high mortality rate from cardiovascular
disease and high complication rate with other vascular
diseases such as cerebrovascular disease [13].
Ankle-brachial blood pressure index (ABI) is a non-
invasive diagnostic tool for early detection of PAD by
measuring blood pressures in both the upper and
lower extremities [14]. ABI is widely utilized for as-
sessment of an artery of the lower extremities since
ABI is easily performed and correlated with angio-
graphic findings of an artery of the lower limb [15].
On the other hand, some reports suggest ABI is not
sufficient for the HD patients with severe blood vessel
calcification or advanced arteriosclerosis to be diag-
nosed as PAD [10, 16].
Recently, skin perfusion pressure (SPP) was used to
detect PAD by Laser Doppler method. Since the skin
circulation regulated by sympathetic nerves is easily
detected by SPP, the condition of microcirculation can
be accurately evaluated by SPP [17]. SPP is also applic-
able to the patients with edema or severe blood vessel
calcification cases as SPP detects circulation of the sub-
cutaneous tissue. SPP has been used for assessment of
wound healing in the field of dermatology [18]. There
are some reports that SPP can evaluate ischemic condi-
tion of the lower extremities which cannot be assessed
by ABI [19]. In this study, both ABI and SPP are mea-
sured in the HD patients and their association with
prognosis is analyzed.
Methods
This study is a retrospective analysis for 45 consecutive
outpatient hemodialysis cases in Nagahara Hospital in
November to December 2006 who were submitted to
evaluation of the ABI and SPP. Clinical and biochemical
data were utilized, including age, gender, duration of
hemodialysis, hemoglobin, calcium, phosphate, parathy-
roid hormone (PTH), and albumin. Cardiac function by
echocardiography was also applied. The patients who
cannot walk on their own or underwent lower limb am-
putation were excluded in this study.
Both SPP and ABI were measured in all the patients
prior to the start of hemodialysis. ABI was determined
by form/ABI (OMRON COLIN, Japan). The systolic
blood pressures were measured at the brachial artery of
the upper limb without the vascular access and at the
posterior tibial arteries of both ankles in the patients
resting in supine position for 5 min. ABI was calculated
from the ratio of the ankle systolic pressure to the bra-
chial one. SPP was evaluated by PAD3000 (KANEKA,
Japan) at the sole of both feet of the patients in supineposition. Both measurements were repeated three times,
and the average values were defined.
The patients were followed between November 2006
and December 2010 with a mean observational period of
44.4 months to evaluate the association of ABI or SPP
value with any-cause mortality.
All data are described as the mean ± SD, and Student’s
t test was used for statistical analysis. Kaplan-Meier ana-
lysis was performed to analyze survival curve. Univariate
and multivariate analyses were performed by logistic
regression analysis in order to identify risk factors for
mortality. A receiver operating characteristic (ROC) ana-
lysis was performed to estimate the cutoff point, sensi-
tivity, and specificity. For all the comparison and
statistical tests, p value less than 0.05 was considered as
statistically significant. All analyses were performed with
the use of Dr. SPSS software version 11.
Results
The clinical and biochemical characteristics of the
patients are shown in Table 1. Average age was 62.7 ±
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male. The mean dialysis duration was 7.3 ± 5.1 years
(0.2–21.5), and diabetes was the primary disease for HD
in 17 patients (38.0%) and currently smoking 5 patients
(11.1%). Some circulatory drugs were medicated: antihy-
pertensive for 37 patients, statin for 5 patients, and
cilostazol for 4 patients. In biochemical analysis, serum
calcium was 9.4 ± 0.7 mg/dl, serum phosphate was 5.1 ±
1.2 mg/dl, serum albumin was 4.1 ± 0.4 g/dl, and
hemoglobin was 10.1 ± 1.0 g/dl. Echocardiographic
values showed left ventricular end-diastolic diameter
(LVDd) at 51.1 ± 5.1 mm, left ventricular ejection frac-
tion (LVEF) at 66.6 ± 9.0%, and left atrial dimension
(LAD) at 37.4 ± 5.2 mm.
Mean ABI and SPP values in all patients were 1.1 ± 0.2
(median 1.15) and 64.7 ± 23.7 mmHg (median 70.0),
respectively. According to ROC analysis, the cutoff value
of ABI was 1.11 (sensitivity, 71%; specificity, 72%), SPP
was 61.8 mmHg (sensitivity, 71%; specificity, 65%).
Although in previous study 40 mmHg was used for cut-
off point of SPP, 61.8 mmHg of the cutoff value showed
better sensitivity and specificity according to ROC
analysis in our study (sensitivity 83.5% and specificity
18.2% in 40 mmHg and sensitivity 26.6% and specificity
81.8% in 80 mmHg). Since both ABI and SPP cutoff
values are similar to median values, we analyzed ABI
and SPP for various factors by using median values.
Patients were classified into two groups for ABI or SPP
results, with the median value used as the cutoff, and
two groups were compared for their characteristics.
Age was significantly different between the higher and
lower SPP groups, although there was no difference inTable 2 Comparison of SPP and ABI lower and higher group in HD
SPP <70 SPP ≥70
(n = 22) (n = 23) p value
Gender (male to female) 13:09 18:05
Age (years) 66.8 ± 14.5 58.7 ± 8.8 0.04
HD duration (years) 8.1 ± 6.1 6.6 ± 4.0 0.32
DM, n (%) 10 (59.0%) 7 (41.0%) 0.31
Current smoking, n (%) 3 (60.0%) 2 (40.0%) 0.91
Statin, n (%) 3 (60.0%) 2 (40.0%) 0.65
Cilostazol, n (%) 3 (75.0%) 1 (25.0%) 0.46
Hb (g/dl) 10.2 ± 1.0 10.0 ± 1.0 0.62
Alb (g/dl) 4.1 ± 0.4 4.2 ± 0.3 0.39
BUN (mg/dl) 68.5 ± 12.1 70.1 ± 12.5 0.65
Cr (mg/dl) 10.3 ± 1.9 12.0 ± 2.1 0.01
P (mg/dl) 4.9 ± 1.2 5.2 ± 1.2 0.43
i-PTH (pg/dl) 170.4 ± 93.5 182.0 ± 129.7 0.71
LVDd (mm) 50.5 ± 5.1 51.8 ± 5.1 0.41
LVEF (%) 64.6 ± 7.1 68.5 ± 10.2 0.15dialysis duration, presence of diabetes, serum albumin,
hemoglobin, serum phosphate, serum calcium, LVDd,
LVEF, or LAD in two groups (Table 2). On the other
hand, age and intact PTH were significantly different
between the higher and lower ABI groups, although
there was no difference in dialysis duration, presence of
diabetes, serum albumin, hemoglobin, serum phosphate,
serum calcium, LVDd, LVEF, or LAD in two groups
(Table 2).
Eleven patients (24.4%) died during the observation
period. All the causes of deaths were circulatory
diseases: heart failure in eight cases (72.7%), acute myo-
cardial infarction in two patients (18.2%), and cerebro-
vascular disease in one patient (9.1%). Mortality rate was
significantly higher in the lower SPP group than that in
the higher one (p < 0.05) while there was no statistical
difference between the higher and lower ABI groups.
Kaplan-Meier analysis was performed for survival
curve to evaluate the ABI and SPP values to predict
prognosis (Fig. 1). While no significant difference was
observed in the survival between the lower and higher
ABI groups, the lower SPP group revealed significantly
worse prognosis than the higher SPP group (p < 0.01).
In the univariate analysis, the predictive variables for
all-caused deaths included age, diabetic status, SPP, ABI,
LVEF, and albumin (p = 0.00, 0.03, 0.02, 0.04, 0.00, and
0.04, respectively). A multivariate cox proportional
hazards model demonstrated SPP, LVEF, and diabetic
status as significantly strong risk factors to all-caused
death (p = 0.02, 0.00 and 0.05, respectively). On the
other hand, age, ABI, and albumin were not inde-
pendent risk factors for mortality (Table 3).patients
ABI <1.15 ABI ≥1.15
(n = 23) (n = 22) p value
Gender (male to female) 15:08 16:06
Age (years) 68.0 ± 11.4 57.7 ± 11.5 0.01
HD duration (years) 8.3 ± 6.2 6.4 ± 3.9 0.56
DM, n (%) 11 (64.7) 6 (53.3) 0.09
Current smoking, n (%) 4 (60.0%) 1 (40.0%) 0.91
Statin, n (%) 3 (60.0%) 2 (40.0%) 0.66
Cilostazol, n (%) 3 (75.0%) 1 (25.0%) 0.44
Hb (g/dl) 10.2 ± 0.9 10.0 ± 1.0 0.62
Alb (g/dl) 4.1 ± 0.3 4.1 ± 0.5 0.39
BUN (mg/dl) 66.9 ± 12.4 71.6 ± 11.8 0.19
Cr (mg/dl) 10.8 ± 2.1 11.4 ± 2.2 0.38
P (mg/dl) 5.1 ± 1.1 5.1 ± 1.3 0.94
i-PTH (pg/dl) 213.1 ± 134.8 142.3 ± 74.4 0.03
LVDd (mm) 50.9 ± 4.7 51.4 ± 5.4 0.71
LVEF (%) 64.6 ± 9.3 68.6 ± 8.4 0.14
Fig. 1 Survival rate of comparison between higher and lower rate of ankle-brachial index (ABI) decline determined using Kaplan-Meier
analysis (a) and SPP (b) are shown
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The patients with classic cardiovascular risk factors have
usually polyvascular disease as PAD, coronary artery dis-
ease [20]. Especially in the patients undergoing HD, the
presence of PAD is reported to increase morbidity and
mortality significantly [21, 22]. Thus, early detection of
PAD is an important issue for the HD patients to predict
mortality [23]. ABI and SPP have been used for the
screening of PAD in the HD patients clinically [8, 10].
ABI has been widely used for detection of PAD by
assessment of arterial stenosis of the lower extremities.
ABI is used commonly and has a merit of the short test-
time as compared with SPP. ABI as early prediction is
particularly important for management of CLI in
patients with suspected peripheral artery disease. [24] It
is reported that ABI is an independent risk factor of
cardiovascular events in PAD patients [25].Table 3 Prognostic factors in the Cox proportional hazards
model
Univariate analysis Multivariate analysis
p value Hazard ratio
(95% CI)
p value Hazard ratio
(95% CI)
Age (years) 0.00 1.1 (1.04–1.16) 0.60 1.0 (0.951–1.090)
DM 0.03 3.8 (1.11–13.07) 0.05 3.9 (1.026–14.869)
SPP <70 mmHg 0.02 6.0 (1.29–27.83) 0.02 7.2 (1.329–39.04)
ABI <1.15 0.04 0.1 (0.01–0.85) 0.94 1.1 (0.04–30.4)
LVDd (mm) 0.26 1.1 (0.95–1.21)
EF (%) 0.00 0.9 (0.85–0.96) 0.00 0.86 (0.79–0.94)
Ca (mg/dl) 0.55 0.57 (0.24–1.39)
P (mg/dl) 0.87 0.77 (0.38–1.54)
i-PTH (pg/dl) 0.64 1.004 (0.99–1.01)
Alb (g/dl) 0.04 0.3 (0.09–0.94) 0.14 0.39 (0.11–1.38)
Hb (g/dl) 0.85 1.1 (0.56–2.01)Since there have been no standardized values for SPP
in the HD patients, some used SPP of 39 mmHg for
diagnosis of PAD as cutoff point [10, 26]. However, they
measured SPP of the dorsal artery of the foot and the
endpoint of the study was the stenosis of the peripheral
artery evaluated by CT scan, which is completely dif-
ferent from our study in both measurement site and
endpoint. In our study for the HD patients without
symptoms of PAD, the cutoff value of SPP was
61.8 mmHg (sensitivity, 71%; specificity, 65%) accord-
ing to ROC analysis. In this study, we used median
values 70 mmHg for the cutoff points of SPP. SPP lower
group showed significantly more cardiac events to clas-
sify HD patients as two groups using 70 mmHg as SPP
cutoff point. We examined only ambulatory patients,
excluding those cases with symptoms of PAD. Our
results demonstrate that SPP would be useful for the
evaluation of mortality risk in the HD patients since
the mortality of the patients with lower SPP values is
significantly higher.
This result is caused by the difference of ABI and SPP
although both methods have been used for detection of
PAD; the conditions of the larger artery are evaluated by
ABI measurement while SPP can detect the state of sub-
cutaneous microcirculation. The lower ABI values reflect
the stenosis of the larger vessels but not of the periph-
eral smaller vessels. On the other hand, SPP is useful for
detection of such patients with normal ABI values as
may be suffered from stenosis of the peripheral smaller
vessels though the larger arteries are not stenotic. ABI
values are elevated as systemic calcification is frequently
found in the HD patients, but SPP values are not influ-
enced by calcification [27]. Therefore, it is possible that
SPP can detect the presence of PAD more accurately
than ABI and SPP values are supposed a risk factor pre-
dicting the prognosis of the HD patients without symp-
toms of PAD.
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limb ischemia among 11 deaths. Two dead patients
suffered from lower limb ulcers. Lower SPP value is
supposed a risk factor of severe ischemic disease in the
lower limb since the patients with higher SPP values do
not suffer from ischemic ulcers. Previous study reported
wound healing is impaired in the patients with SPP value
of 30 mmHg [18]. The preservation of microcirculation
is important for the prevention of death from infection.
We analyzed risk factors to predict prognosis of the
HD patient. As a result, SPP values as well as diabetic
status and LVEF were independent risk factors by multi-
variate analysis. There have been many reports that the
presence of diabetes increased mortality for the HD
patients since diabetes was a risk factor for coronary
artery disease, and diabetic patients suffered from infec-
tion due to severe ischemic PAD [8]. The patients with
lower LVEF have higher risk for heart failure which is a
frequent cause of death for the HD patients [28].
Furthermore, our results also indicated SPP values for
important risk factors and hazard ratio of SPP values
was higher than that of diabetes or LVEF. These results
suggest that preservation of circulation in the peripheral
smaller blood vessels in the lower extremities is import-
ant to improve the prognosis of the HD patients as well
as circulation of the larger vessels. Furthermore, the
screening of peripheral blood circulation by SPP is useful
to those HD patients who showed decreased circulation
in the peripheral vessels in the lower extremities. Since
our study has a limitation of one single institute study
with smaller number of HD patients, validation of multi-
center study with larger number of patients will be
required.
Conclusions
We studied the effectiveness of SPP to predict the prog-
nosis of HD patients. The lower SPP group showed
significantly worse survival curve than the higher SPP
group while there were no differences between the
higher and lower ABI groups. Cox proportional hazards
model demonstrated SPP values, LVEF, and diabetes are
independent and significant risk factors for mortality.
These results suggest evaluation of PAD by SPP meas-
urement is useful to predict prognosis of HD patients.
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